La aplicación de los inhibidores del cotransportador sodioglucosa en la mejoría de pacientes con insuficiencia cardiaca del Hospital Teodoro Maldonado Carbo entre el año 2021 y 2022.

Abstract

Introduction: Based on clinical trials such as EMPA-REG OUTCOME and CANVAS, We found that ISGLT2 are effective in preventing major adverse cardiovascular events in the medium and long term, especially in HF. Objective: Evaluate the use of inhibitors sodium glucose cotransporter type 2, in patients with HF. Materials and methods: A non-randomized, retrospective and longitudinal case-control study was carried out using the medical records of patients diagnosed with heart failure at Teodoro Maldonado Carbo Hospital between 2021 and 2022. The initial population was 500 patients with diagnosis of HF that have been evaluated by the specialization of cardiology, of which, applying the inclusion and exclusion criteria left us with 61 patients for the case group and we randomly chose 61 patients for the control group, giving a total sample of 122 patients for our study. Results: Within the group of cases we found that 31.1% are male and 18.9% are female. In the control group, 32.8% are male and 17.2% are female. an association was found between HF improvement and the consumption of ISGLT2 drugs (p=0.000). Within the efficacy that one ISGLT2 drug could have over another, we found that there was no statistically significant difference (p=0.830). Conclusion: To conclude, the use of an SGLT2 inhibitor drug associated with conventional treatment for HF significantly improves the ejection fraction of these patients.